Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214857) titled 'Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States' on Oct. 6.

Study Type: Observational

Primary Sponsor: Novartis Pharmaceuticals

Condition: Cardiovascular Disease

Recruitment Status: Not recruiting

Date of First Enrollment: March 29, 2024

Target Sample Size: 1385

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07214857

Published by HT Digital Content Services with permission from Health Daily Digest....